US Stock MarketDetailed Quotes

VRTX Vertex Pharmaceuticals

Watchlist
  • 459.000
  • -3.580-0.77%
Close Feb 14 16:00 ET
  • 459.000
  • 0.0000.00%
Post 20:01 ET
117.87BMarket Cap-220.67P/E (TTM)

About Vertex Pharmaceuticals Company

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Company Profile

SymbolVRTX
Company NameVertex Pharmaceuticals
Listing DateJul 4, 1991
Issue Price13.75
Founded1989
CEODr. Reshma Kewalramani, M.D.
MarketNASDAQ
Employees6100
Fiscal Year Ends12-31
Address50 Northern Avenue
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02210
Phone1-617-341-6100

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Reshma Kewalramani, M.D.
  • Director, President and Chief Executive Officer
  • 20.59M
  • Dr. E Morrow Atkinson, III, PhD
  • Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Science and Manufacturing Operations
  • --
  • Charles F. Wagner, Jr
  • Executive Vice President and Chief Financial Officer
  • 7.37M
  • Carmen Bozic
  • Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
  • --
  • Dr. Ourania Tatsis, PhD
  • Executive Vice President and Chief Regulatory and Quality Officer
  • --
  • Jonathan Biller
  • Executive Vice President and Chief Legal Officer
  • --
  • Dr. David Altshuler
  • Executive Vice President, Global Research and Chief Scientific Officer
  • 6.54M
  • Amit K. Sachdev, J.D.
  • Executive Vice President and Chief Patient and External Affairs Officer
  • --
  • Stuart A. Arbuckle
  • Executive Vice President and Chief Operating Officer
  • 9.00M
  • Kristen Ambrose
  • Senior Vice President and Chief Accounting Officer
  • --
  • Duncan J. McKechnie
  • Senior Vice President and Head, North America Commercial Team
  • --
  • Dr. Jeffrey M Leiden, PhD
  • Executive Chairman of the Board
  • 6.60M
  • Bruce I. Sachs
  • Lead Independent Director
  • 600.04K
  • Dr. Sangeeta N. Bhatia, PhD
  • Independent Director
  • 550.31K
  • Nancy A. Thornberry
  • Independent Director
  • 407.65K
  • Diana L. McKenzie
  • Independent Director
  • 553.11K
  • Suketu Upadhyay
  • Independent Director
  • 544.66K
  • Dr. Alan M. Garber, M.D.,PhD
  • Independent Director
  • 537.63K
  • Dr. Jennifer Schneider, M.D.
  • Independent Director
  • --
  • Michel Lagarde
  • Independent Director
  • 449.08K
  • Lloyd A. Carney
  • Independent Director
  • 559.79K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Major earnings are approaching! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1 Show More